ABCL - AbCellera Biologics Inc.
3.45
-0.140 -4.058%
Share volume: 4,271,247
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.14%
PREVIOUS CLOSE
CHG
CHG%
$3.59
-0.14
-0.04%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-07-2024 | 08-06-2024 | 11-04-2024 | 02-27-2025 | 05-08-2025 | 11-06-2025 | 02-24-2026 | |
| Assets | ||||||||
| Total Assets | 1.463 B | 1.412 B | 1.393 B | 1.361 B | 1.344 B | 1.356 B | 1.357 B | |
| Current Assets | 813.948 M | 771.554 M | 742.883 M | 751.370 M | 764.978 M | 695.140 M | 728.232 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 56.506 M | 40.055 M | 43.371 M | 67.140 M | 94.707 M | 133.012 M | 111.113 M | |
| Short Term Investments | 574.451 M | 522.044 M | 516.499 M | 469.289 M | 446.000 M | 412.513 M | 405.313 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 123.572 M | 148.312 M | 126.640 M | 156.325 M | 159.266 M | 83.159 M | 128.513 M | |
| Total Non-current Assets | 71.592 M | 76.064 M | 84.084 M | 82.297 M | 81.567 M | 93.301 M | 62.580 M | |
| Property Plant Equipment | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Assets | 649.148 M | 640.927 M | 649.945 M | 609.183 M | 579.230 M | 660.852 M | 628.718 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | ||||||||
| Total Liabilities and shareholders’ equity | 1.463 B | 1.412 B | 1.393 B | 1.361 B | 1.344 B | 1.356 B | 1.357 B | |
| Total liabilities | 333.183 M | 301.513 M | 314.734 M | 304.469 M | 321.226 M | 391.954 M | 390.046 M | |
| Total current liabilities | 104.883 M | 70.380 M | 79.568 M | 76.612 M | 75.396 M | 68.804 M | 64.307 M | |
| Accounts Payable | 42.887 M | 43.952 M | 53.773 M | 55.004 M | 47.840 M | 53.117 M | 50.781 M | |
| Other liabilities | 189.456 M | 201.426 M | 214.285 M | 212.105 M | 222.027 M | 307.556 M | 316.624 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 189.456 M | 201.426 M | 214.285 M | 212.105 M | 222.027 M | 307.556 M | 316.624 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 1.130 B | 1.111 B | 1.078 B | 1.056 B | 1.023 B | 964.038 M | 966.904 M | |
| Common stock | 892.552 M | 910.794 M | 928.186 M | 943.532 M | 958.671 M | 987.273 M | 1.001 B | |
| Retained earnings | 239.177 M | 202.247 M | 151.140 M | 116.930 M | 71.309 M | -20.537 M | -29.482 M |